{"id":295311,"date":"2026-03-16T00:00:00","date_gmt":"2026-03-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0007-2023-biopharma-prostate-cancer-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-04-29T23:09:18","modified_gmt":"2026-04-29T23:09:18","slug":"cutron0007-2026-biopharma-prostate-cancer-current-treatment-current-treatment-physician-insights-prostate-cancer-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0007-2026-biopharma-prostate-cancer-current-treatment-current-treatment-physician-insights-prostate-cancer-us\/","title":{"rendered":"Prostate Cancer &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Prostate Cancer (US)"},"content":{"rendered":"<p>Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with <abbr title=\"androgen deprivation therapy\">ADT<\/abbr> serving as the universal backbone. <abbr title=\"androgen receptor pathway inhibitor\">ARPI<\/abbr>s\u2014enzalutamide, apalutamide, and darolutamide\u2014drive treatment in <abbr title=\"nonmetastatic castrate-resistant prostate cancer\">nmCRPC<\/abbr> and <abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr> and remain widely used in <abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr>, although earlier-line intensification has shifted some use upstream. Chemotherapy continues to play a key role in advanced disease, while radioligand therapy is reshaping treatment options through the expanding use of Pluvicto in <abbr title=\"prostate-specific membrane antigen\">PSMA<\/abbr>-positive <abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr>. <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitors, including olaparib, talazoparib, and niraparib, offer important biomarker-selected options for patients with<em> <\/em><em><abbr title=\"homologous repair recombination\">HRR<\/abbr><\/em>-mutated <abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr> and contribute to growing segmentation within the market. With multiple agents competing across lines of therapy and clinical factors strongly influencing selection, understanding real-world physician prescribing is essential for navigating today\u2019s prostate cancer landscape.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the current drug-treatment rates and patient shares of key therapies across key prostate cancer populations?<\/li>\n<li>What considerations influence physicians\u2019 choice among enzalutamide, darolutamide, and apalutamide for <abbr title=\"metastatic hormone-sensitive prostate cancer\">mHSPC<\/abbr>?<\/li>\n<li>Which clinical factors most strongly drive physicians\u2019 prescribing of <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitors for <abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr> <abbr title=\"homologous repair recombination\">HRR<\/abbr>-mutated patients, and what obstacles\u2014clinical, operational, or access-related\u2014limit broader utilization?<\/li>\n<li>What benefits, requirements, and barriers do physicians report when considering Pluvicto for pre- and post-taxane <abbr title=\"metastatic castrate-resistant prostate cancer\">mCRPC<\/abbr>, and how do these factors shape its current positioning in practice?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>Primary research: <\/strong>Survey of 100 medical oncologists in the United States fielded in December 2025.<\/p>\n<p><strong>Key drugs covered: <\/strong>Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Docetaxel, Cabazitaxel, Olaparib, Niraparib, Talazoparib, 177Lu-<abbr title=\"prostate-specific membrane antigen\">PSMA<\/abbr>-617.<\/p>\n","protected":false},"template":"","class_list":["post-295311","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295311\/revisions"}],"predecessor-version":[{"id":575177,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295311\/revisions\/575177"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}